Cargando…

Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence

PURPOSE: The safety and efficacy of the several types of COVID-19 vaccines, including mRNA-based, viral vector-based, and inactivated vaccines, have been approved by WHO. The vaccines can confer protection against severe SARS-CoV-2 infection through induction of the anti-spike protein neutralizing a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jafarzadeh, A., Nemati, M., Jafarzadeh, S., Nozari, P., Mortazavi, S. M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960081/
https://www.ncbi.nlm.nih.gov/pubmed/35347651
http://dx.doi.org/10.1007/s40618-022-01786-7
_version_ 1784677310428872704
author Jafarzadeh, A.
Nemati, M.
Jafarzadeh, S.
Nozari, P.
Mortazavi, S. M. J.
author_facet Jafarzadeh, A.
Nemati, M.
Jafarzadeh, S.
Nozari, P.
Mortazavi, S. M. J.
author_sort Jafarzadeh, A.
collection PubMed
description PURPOSE: The safety and efficacy of the several types of COVID-19 vaccines, including mRNA-based, viral vector-based, and inactivated vaccines, have been approved by WHO. The vaccines can confer protection against severe SARS-CoV-2 infection through induction of the anti-spike protein neutralizing antibodies. However, SARS-CoV-2 vaccines have been associated with very rare complications, such as thyroid disorders. This review was conducted to highlight main features of thyroid abnormalities following COVID-19 vaccination. METHODS: A comprehensive search within electronic databases was performed to collect reports of thyroid disorders after vaccination with COVID-19 vaccines. RESULTS: Among 83 reported cases including in this review, the most cases of thyroid abnormalities were observed after vaccination with mRNA-based vaccines (68.7%), followed by viral vector vaccines (15.7%) and 14.5% cases following inactivated vaccines. Subacute thyroiditis (SAT) was the most common COVID-19 vaccination-related thyroid disease, accounting for 60.2% of all cases, followed by Graves' disease (GD) with 25.3%. Moreover, some cases with focal painful thyroiditis (3.6%), silent thyroiditis (3.6%), concurrent GD and SAT (2.4%), thyroid eye disease (1.2%), overt hypothyroidism (1.2%), atypical subacute thyroiditis (1.2%), and painless thyroiditis with TPP (1.2%) were also reported. Overall, in 58.0% of SAT cases and in 61.9% of GD cases, the onset of the symptoms occurred following the first vaccine dose with a median of 10.0 days (ranged: 3–21 days) and 10.0 days (ranged: 1–60 days) after vaccination, respectively. Moreover, 40.0% of SAT patients and 38.1% of GD patients developed the symptoms after the second dose with a median of 10.5 days (ranged: 0.5–37 days) and 14.0 days (ranged: 2–35 days) after vaccination, respectively. CONCLUSION: Fortunately, almost all cases with COVID-19 vaccination-associated thyroid dysfunctions had a favorable outcome following therapy. The benefits of COVID-19 vaccinations in terms of terminating the pandemic and/or reducing mortality rates can exceed any risk of infrequent complications such as a transient thyroid malfunction.
format Online
Article
Text
id pubmed-8960081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89600812022-03-29 Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence Jafarzadeh, A. Nemati, M. Jafarzadeh, S. Nozari, P. Mortazavi, S. M. J. J Endocrinol Invest Review PURPOSE: The safety and efficacy of the several types of COVID-19 vaccines, including mRNA-based, viral vector-based, and inactivated vaccines, have been approved by WHO. The vaccines can confer protection against severe SARS-CoV-2 infection through induction of the anti-spike protein neutralizing antibodies. However, SARS-CoV-2 vaccines have been associated with very rare complications, such as thyroid disorders. This review was conducted to highlight main features of thyroid abnormalities following COVID-19 vaccination. METHODS: A comprehensive search within electronic databases was performed to collect reports of thyroid disorders after vaccination with COVID-19 vaccines. RESULTS: Among 83 reported cases including in this review, the most cases of thyroid abnormalities were observed after vaccination with mRNA-based vaccines (68.7%), followed by viral vector vaccines (15.7%) and 14.5% cases following inactivated vaccines. Subacute thyroiditis (SAT) was the most common COVID-19 vaccination-related thyroid disease, accounting for 60.2% of all cases, followed by Graves' disease (GD) with 25.3%. Moreover, some cases with focal painful thyroiditis (3.6%), silent thyroiditis (3.6%), concurrent GD and SAT (2.4%), thyroid eye disease (1.2%), overt hypothyroidism (1.2%), atypical subacute thyroiditis (1.2%), and painless thyroiditis with TPP (1.2%) were also reported. Overall, in 58.0% of SAT cases and in 61.9% of GD cases, the onset of the symptoms occurred following the first vaccine dose with a median of 10.0 days (ranged: 3–21 days) and 10.0 days (ranged: 1–60 days) after vaccination, respectively. Moreover, 40.0% of SAT patients and 38.1% of GD patients developed the symptoms after the second dose with a median of 10.5 days (ranged: 0.5–37 days) and 14.0 days (ranged: 2–35 days) after vaccination, respectively. CONCLUSION: Fortunately, almost all cases with COVID-19 vaccination-associated thyroid dysfunctions had a favorable outcome following therapy. The benefits of COVID-19 vaccinations in terms of terminating the pandemic and/or reducing mortality rates can exceed any risk of infrequent complications such as a transient thyroid malfunction. Springer International Publishing 2022-03-26 2022 /pmc/articles/PMC8960081/ /pubmed/35347651 http://dx.doi.org/10.1007/s40618-022-01786-7 Text en © The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE) 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Jafarzadeh, A.
Nemati, M.
Jafarzadeh, S.
Nozari, P.
Mortazavi, S. M. J.
Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title_full Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title_fullStr Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title_full_unstemmed Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title_short Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
title_sort thyroid dysfunction following vaccination with covid-19 vaccines: a basic review of the preliminary evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960081/
https://www.ncbi.nlm.nih.gov/pubmed/35347651
http://dx.doi.org/10.1007/s40618-022-01786-7
work_keys_str_mv AT jafarzadeha thyroiddysfunctionfollowingvaccinationwithcovid19vaccinesabasicreviewofthepreliminaryevidence
AT nematim thyroiddysfunctionfollowingvaccinationwithcovid19vaccinesabasicreviewofthepreliminaryevidence
AT jafarzadehs thyroiddysfunctionfollowingvaccinationwithcovid19vaccinesabasicreviewofthepreliminaryevidence
AT nozarip thyroiddysfunctionfollowingvaccinationwithcovid19vaccinesabasicreviewofthepreliminaryevidence
AT mortazavismj thyroiddysfunctionfollowingvaccinationwithcovid19vaccinesabasicreviewofthepreliminaryevidence